satavaptan Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Satavaptan is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009.   Wikipedia

Chemistry

  • SMILES: CCOc1ccc2N(C(=O)[C@@]3(CC[C@H](CCN4CCOCC4)CC3)c2c1)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C
  • InChIKey: CDSBFDCCJJDFCV-CKZSCMLPSA-N
  • Mol. Mass: 627.8
  • ALogP: 4.51
  • ChEMBL Molecule:
    satavaptan  
More Chemistry

Pharmacology

Alternative names

1-(4-(n-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro-(4-(2-morpholinoethoxy)cyclohexane)indol-2-one fumarate | 1-(4-(n-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro(4-(2-morpholinoethoxy)cyclohexane)indoline-2-one, phosphate monohydrate cis-isomer | satavaptan | sr-121463 | sr 121463a | sr-121463a | sr121463b | sr-121463b | sr-121463f

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Ascites (Phase 3)

Heart Failure (Phase 3)

Hyponatremia (Phase 3)

Inappropriate ADH Syndrome (Phase 3)

Liver Cirrhosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue